Illumina Inc. has announced the release of its novel 5-base solution, a significant advancement in multiomic analysis that enables researchers to simultaneously detect genomic variants and DNA methylation from a single sample. This new technology streamlines workflows and reduces costs, potentially accelerating research in areas such as rare disease, cancer, and precision medicine. The scientific research results demonstrating the power of the 5-base genome for resolving rare disease cases will be presented by Dr. Bekim Sadikovic at the American Society of Human Genetics (ASHG) annual meeting on October 15.